医学临床研究
  2025年4月3日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (3): 349-351    DOI: 10.3969/j.issn.1671-7171.2022.03.008
  论著 本期目录 | 过刊浏览 | 高级检索 |
血清Nesfatin-1水平与2型糖尿病合并高血压患者发生轻度认知功能障碍的相关性
刘小阳, 郑桃林**, 刘超, 龙艳, 余承裕, 万华平, 邢红专, 范方松, 秦惠惠
中国人民解放军联勤保障部队第九二一医院,湖南 长沙 410003
Relationship between Serum Nesfatin-1 Level and Mild Cognitive Impairment in Patients with Type 2 Diabetes Mellitus Complicated with Hypertension
LIU Xiao-yang, ZHENG Tao-lin, LIU Chao, et al
The 921th Hospital of PLA, Changsha Hunan 410003
全文: PDF (1114 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨血清摄食抑制因子(Nesfatin-1)水平与2 型糖尿病(T2DM)合并高血压患者发生轻度认知功能障碍(MCI)的相关性。【方法】选择2018年12月至2020年1月本院收治的786例老年T2DM患者,将其分为单纯T2DM组(A组)、T2DM +高血压亚组(B1亚组)和T2DM +高血压+MCI亚组(B2亚组)。比较各组患者空腹血糖(FPG)、空腹胰岛素、同型半胱氨酸(Hcy)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、高敏C反应蛋白(hs-CRP)、神经元烯醇化酶(NSE)、糖化血红蛋白(HbA1c)、Nesfatin-1水平,并计算胰岛素敏感指数(ISI)。采用Logistic多因素回归分析影响老年T2DM合并高血压患者发生MCI的相关危险因素。【结果】B1亚组、B2亚组FPG、Nesfatin-1、LDL-C、ISI、Hcy水平与A组比较,差异有统计学意义(P<0.05);B2亚组BMI、FPG、Nesfatin-1、ISI、LDL-C、NSE水平与B1亚组比较,差异有统计学意义(P<0.05),且NSE水平显著高于A组(P<0.05)。 Pearson相关分析显示,血清Nesfatin-1与BMI、FPG、HbA1c、NSE、Hcy呈正相关(P<0.05),与ISI呈负相关(P<0.05)。Logistic多因素回归分析显示,FPG、BMI、Nesfatin-1为T2DM合并高血压患者发生MCI的危险因素。【结论】血清Nesfatin-1水平及FPG、BMI是T2DM合并高血压患者发生MCI的危险因素,有效地控制体重,改善FPG水平,增加胰岛素敏感性对此类患者具有重要意义。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 糖尿病, 2型/合并症高血压/合并症蛋白质类/血液认知功能障碍    
Abstract:【Objective】To investigate the correlation between serum Nesfatin-1 level and mild cognitive impairment in patients with Type 2 diabetes mellitus complicated with hypertension. 【Methods】A total of 786 elderly patients with T2DM treated in our hospital from December 2018 to January 2020 were divided into simple T2DM group (group A), T2DM + hypertension subgroup (subgroup B1) and T2DM + hypertension + MCI subgroup (subgroup B2). The levels of fasting blood glucose (FPG), fasting insulin, homocysteine (Hcy), total cholesterol (TC), low density lipoprotein (LDL-C), triglyceride (TG), high density lipoprotein (HDL-C), high sensitivity C-reactive protein (hs-CRP), neuronal enolase (NSE), glycosylated hemoglobin (HbA1c) and Nesfatin-1 were compared, and the insulin sensitivity index (ISI) was calculated. Logistic multivariate regression analysis was used to analyze the related risk factors of MCI in elderly T2DM patients with hypertension. 【Results】 The levels of FPG, Nesfatin-1, LDL-C, ISI and Hcy in the B1 subgroup and the B2 subgroup were significantly higher than those in the group A (P<0.05); The levels of BMI, FPG, Nesfatin-1, ISI, LDL-C and NSE in the subgroup B2 were significantly higher than those in the subgroup B1 (P<0.05), and the level of NSE was significantly higher than that in the group A (P<0.05). Pearson correlation analysis showed that serum Nesfatin-1 was positively correlated with BMI, FPG, HbA1c, NSE and Hcy (P<0.05), and negatively correlated with ISI (P<0.05). Logistic multivariate regression analysis showed that FPG, BMI and Nesfatin-1 were the risk factors of MCI in T2DM patients with hypertension. 【Conclusion】 Serum Nesfatin-1 level, FPG and BMI are the risk factors of MCI in T2DM patients with hypertension. It is of great significance to effectively control body weight, improve fasting blood glucose level and increase insulin sensitivity.
Key wordsDiabetes Mellitus, Type 2/CO    Hypertension/CO    Proteins/BL    Cognitive Dysfunction
收稿日期: 2021-05-18     
中图分类号:  R587.1  
基金资助:湖南省教育厅科学研究项目(20C1152);长沙市科技计划(kq1801113)
通讯作者: ** E-mail:hanshi163007@163.com   
引用本文:   
刘小阳, 郑桃林, 刘超, 龙艳, 余承裕, 万华平, 邢红专, 范方松, 秦惠惠. 血清Nesfatin-1水平与2型糖尿病合并高血压患者发生轻度认知功能障碍的相关性[J]. 医学临床研究, 2022, 39(3): 349-351.
LIU Xiao-yang, ZHENG Tao-lin, LIU Chao, et al. Relationship between Serum Nesfatin-1 Level and Mild Cognitive Impairment in Patients with Type 2 Diabetes Mellitus Complicated with Hypertension. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 349-351.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.008     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/349
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn